NTRK1 and rhabdomyosarcoma: FGFR4 is a receptor tyrosine kinase overexpressed in rhabdomyosarcoma (RMS) and mutationally activated in ~10% of FN-RMS cases.42 Recently, Wu et al42 have demonstrated that futibatinib is a potent inhibitor of FGFR4 and impedes growth of RMS cell lines expressing wild-type and mutant FGFR4 in vitro.